BIB vs. XBI
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and SPDR S&P Biotech ETF (XBI).
BIB and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. Both BIB and XBI are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIB or XBI.
Key characteristics
| BIB | XBI | |
|---|---|---|
| YTD Return | -12.89% | -6.50% |
| 1Y Return | -9.08% | 5.97% |
| 3Y Return (Ann) | -18.51% | -15.71% |
| 5Y Return (Ann) | -0.42% | -0.82% |
| 10Y Return (Ann) | 2.98% | 7.21% |
| Sharpe Ratio | -0.26 | 0.19 |
| Daily Std Dev | 32.95% | 28.16% |
| Max Drawdown | -67.24% | -63.89% |
| Current Drawdown | -55.38% | -51.99% |
Correlation
The correlation between BIB and XBI is 0.91, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
BIB vs. XBI - Performance Comparison
In the year-to-date period, BIB achieves a -12.89% return, which is significantly lower than XBI's -6.50% return. Over the past 10 years, BIB has underperformed XBI with an annualized return of 2.98%, while XBI has yielded a comparatively higher 7.21% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. XBI - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than XBI's 0.35% expense ratio.
Risk-Adjusted Performance
BIB vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIB vs. XBI - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.16%, more than XBI's 0.02% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.16% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.02% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
Drawdowns
BIB vs. XBI - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, which is greater than XBI's maximum drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for BIB and XBI. For additional features, visit the drawdowns tool.
Volatility
BIB vs. XBI - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 9.46% compared to SPDR S&P Biotech ETF (XBI) at 7.05%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.